Skeletal muscle wasting in chronic heart failure

Area of Science:

• Gerontology and Cardiology
• Muscle Physiology and Disease

Background:

• Sarcopenia (loss of muscle mass and function) is prevalent in elderly individuals, particularly those with chronic heart failure (CHF), affecting up to 50% of octogenarians.
• Sarcopenia is a significant predictor of frailty, disability, and mortality in older adults.
• In CHF patients, sarcopenia is linked to reduced physical strength, lower peak oxygen consumption (VO2), and decreased exercise tolerance.

Purpose of the Study:

• To review the challenges and emerging therapeutic strategies for sarcopenia and muscle wasting in the context of chronic heart failure.
• To highlight the limitations of current interventions and the need for novel treatments.

Main Methods:

• Literature review of studies on sarcopenia in elderly populations and CHF patients.
• Analysis of the association between sarcopenia and clinical outcomes in CHF.
• Examination of current and investigational therapeutic options for muscle wasting.

Main Results:

• Sarcopenia is common in CHF patients, correlating with poorer physical function and exercise capacity.
• Resistance exercise and nutritional support are primary interventions, but their efficacy can be limited.
• Low endogenous testosterone is an independent risk factor in CHF, though testosterone therapy has potential side effects.

Conclusions:

• Effective treatments for sarcopenia in CHF are limited, necessitating further research into novel therapeutic agents.
• Investigational drugs targeting pathways like androgen receptors, growth hormone, IGF-1, and myostatin show promise for future therapies.
• Addressing muscle wasting in CHF and cardiac cachexia remains a critical and active area of clinical research.